HNSA-5487, Hansa Biopharma’s experimental treatment for neuromyelitis optica spectrum disorder (NMOSD) and other autoimmune diseases, safely and effectively…
Margarida Maia, PhD
Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Margarida Maia, PhD
Combining blood-cleaning therapies such as plasma exchange or immunoadsorption with standard steroid treatment can improve recovery outcomes in patients having…
People having area postrema syndrome (APS), that is, uncontrollable nausea, vomiting, or hiccups, as the first symptom of neuromyelitis…
People with neuromyelitis optica spectrum disorder (NMOSD) have significantly lower vitamin D levels in their blood than do healthy…
Most neuromyelitis optica spectrum disorder (NMOSD) patients who start taking Enspryng (satralizumab) remain free of relapses for at…
People who develop neuromyelitis optica spectrum disorder (NMOSD) at an older age are more likely to experience spinal cord…
Tocilizumab, an anti-inflammatory medication used off-label for neuromyelitis optica spectrum disorder (NMOSD), can help prevent relapses (flare-ups) and ease…
Health Canada has approved Uplizna (inebilizumab-cdon) to treat adults in the country with neuromyelitis optica spectrum disorder (NMOSD)…
About 1 in 10 people who are hospitalized for neuromyelitis optica spectrum disorder (NMOSD) are readmitted to the hospital…
People with a genetic makeup that causes them to be more susceptible to COVID-19 are nearly five times as likely…